<DOC>
	<DOCNO>NCT02300233</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety volanesorsen give 26 week patient Hypertriglyceridemia</brief_summary>
	<brief_title>The COMPASS Study : A Study Volanesorsen ( Formally ISIS-APOCIIIRx ) Patients With Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>1 . BMI ≤ 45 kg/m2 2 . Fasting TG ≥ 500 mg/dL ( ≥ 5.7 mmol/L ) Screening . 3 . If statin fibrate , patient must stable , label dose least 3 month prior screen . Patients receive drug within 4 week prior screen also eligible . 1 . Type 1 diabetes mellitus 2 . Newly diagnose type 2 diabetes mellitus ( within 12 week screen ) HbA1c ≥ 9.0 % Screening 3 . Acute pancreatitis within 3 month screen 4 . Acute Coronary Syndrome within 6 month screen 5 . Major surgery within 3 month screen 6 . Prior exposure ISIS 304801 7 . Have condition opinion investigator could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>